Serum ischemia modified albumin and endometrial cancer: a prospective case-control study
MetadataShow full item record
Objective: To investigate the importance of ischemia modified albumin (IMA) in the diagnosis and evaluation of endometrial carcinoma. Material and Methods: Serum IMA levels of patients with and without endometrial cancer were measured by the calorimetric assay technique and their absorbance units were compared. Results: A total of 128 women were included in the study; 64 of these women were endometrial cancer patients and 64 of them were in the control group. The median age for these groups were 58.5 and 56 years, respectively. There was no significant difference in terms of age, body mass index, and serum albumin levels between the groups (p > 0.05). In the endometrial cancer group, the median serum IMA level was 0.489 (0.401-0.611), while in the control group the median serum IMA level was 0.490 (0.407-0.589). There was no significant difference between these two groups (p = 0.467). In the type 1 endometrial cancer group, the median serum IMA level was 0.452 (0.401-0.590), while in the type 2 endometrial cancer group the median serum IMA level was 0.559 (0.462-0.611) A significant difference was found between types 1 and 2 endometrial cancers (p < 0.001). Conclusions: The IMA level does not appear to be an additional predictive marker of preoperative diagnosis and evaluation of endometrioid type endometrial cancer when compared to the healthy control group; on the other hand, IMA may be a marker for the detection of type 2 endometrium cancers when compared with type 1 endometrium tumors. However, further randomized controlled trials are required to make a comparison between type1 and type2 endometrial cancers.